ES8802582A1 - Un metodo para estabilizar un precursor de activador de plasminogeno. - Google Patents

Un metodo para estabilizar un precursor de activador de plasminogeno.

Info

Publication number
ES8802582A1
ES8802582A1 ES551324A ES551324A ES8802582A1 ES 8802582 A1 ES8802582 A1 ES 8802582A1 ES 551324 A ES551324 A ES 551324A ES 551324 A ES551324 A ES 551324A ES 8802582 A1 ES8802582 A1 ES 8802582A1
Authority
ES
Spain
Prior art keywords
salts
precursor
plasminogen activator
stabilized
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES551324A
Other languages
English (en)
Spanish (es)
Other versions
ES551324A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Publication of ES8802582A1 publication Critical patent/ES8802582A1/es
Publication of ES551324A0 publication Critical patent/ES551324A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES551324A 1985-01-30 1986-01-28 Un metodo para estabilizar un precursor de activador de plasminogeno. Expired ES8802582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60017077A JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Publications (2)

Publication Number Publication Date
ES8802582A1 true ES8802582A1 (es) 1988-08-16
ES551324A0 ES551324A0 (es) 1988-08-16

Family

ID=11933913

Family Applications (1)

Application Number Title Priority Date Filing Date
ES551324A Expired ES8802582A1 (es) 1985-01-30 1986-01-28 Un metodo para estabilizar un precursor de activador de plasminogeno.

Country Status (6)

Country Link
US (1) US5075230A (https=)
EP (1) EP0190041A3 (https=)
JP (1) JPS61176532A (https=)
KR (1) KR940000540B1 (https=)
CA (1) CA1283047C (https=)
ES (1) ES8802582A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336585C (en) * 1985-04-16 1995-08-08 Kazuo Morimoto Method of stabilizing urokinase precursor and dry preparation containing said precursor
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) * 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137343B2 (https=) * 1972-12-07 1976-10-15
US4245051A (en) * 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
NL7812336A (nl) * 1978-12-20 1980-06-24 Methanol Chemie Nederland Bereiding van spaanplaat.
JPS5668607A (en) * 1979-11-07 1981-06-09 Teikoku Hormone Mfg Co Ltd Medical preparation with storage stability
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
JPS58170354A (ja) * 1982-03-30 1983-10-06 Hitachi Ltd リニヤ・アクチユエ−タ
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3486023T2 (de) * 1983-09-13 1993-06-24 Green Cross Corp Verfahren zur herstellung von urokinase zymogen.
EP0151996B1 (en) * 1984-01-30 1991-04-03 Asahi Kasei Kogyo Kabushiki Kaisha Process for the preparation of a double-chain plasminogen activator
CA1336585C (en) * 1985-04-16 1995-08-08 Kazuo Morimoto Method of stabilizing urokinase precursor and dry preparation containing said precursor

Also Published As

Publication number Publication date
KR860005884A (ko) 1986-08-13
JPH0479326B2 (https=) 1992-12-15
KR940000540B1 (ko) 1994-01-24
EP0190041A3 (en) 1988-09-28
CA1283047C (en) 1991-04-16
JPS61176532A (ja) 1986-08-08
EP0190041A2 (en) 1986-08-06
US5075230A (en) 1991-12-24
ES551324A0 (es) 1988-08-16

Similar Documents

Publication Publication Date Title
ES8802582A1 (es) Un metodo para estabilizar un precursor de activador de plasminogeno.
ES8800343A1 (es) Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia
ES8705842A1 (es) Procedimiento para la preparacion biotecnologica de acidos alfa-arilalcanoicos activos opticamente
DE69027526D1 (de) Herstellung von proteinen mittels homologer rekombination
SE8000243L (sv) Typ ii-interferon och medel innehallande detsamma
CL2008000584A1 (es) Procedimiento de preparacion de esteres dialquilicos de acidos alquil-amido-tiofosforicos que comprende la reaccion de un ditiofosfato con agente de oxidacion en solucion de caracter acido y reaccion del producto obtenido con una amina (divisional de
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
DK176285D0 (da) Fremstilling af polypeptider med human-gamma-interferonaktivitet
MX2025011493A (es) Composiciones y metodos para el direccionamiento a pcsk9
GB1522006A (en) Feline calicivirus vaccine and a process for the production thereof
DK237985D0 (da) Genteknologisk fremgangsmaade til fremstilling af human-interleukin-2 og middel til gennemfoerelse af fremgangsmaaden
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
MX173840B (es) Procedimiento para producir una enzima de alfa-amilasa
NO884549D0 (no) Fremgangsmaate ved fremstilling av proteiner.
ES8706821A1 (es) Metodo de estabilizar un precursor de uroquinasa
ES2042988T3 (es) Acidos 1h-indazol-3-aceticos como inhibidores de aldosareductasa.
DK627587D0 (da) Fremgangsmaade til fremstilling af 2-arylprpionsyrer og mikroorganismer anvendt ved denne fremgangsmaade
ES8101646A1 (es) Un procedimiento para producir un compuesto opticamente ac- tivo
NO890761L (no) Nye tiorodaminer og en ny fremgangsmaate for deres fremstilling.
BR9808472A (pt) Método de produção de proteìna heteróloga
SU497837A1 (ru) Способ получени внеклеточной неспецифической кислой рибонуклеазы
DK104390D0 (da) Vaevs-plasminogen aktivatorforbindelse, dna, der koder herfor, udtrykkelsesvektor indeholdende dette dna, vaertsceller transformeret med udtrykkelsesvektoren, fremgangsmaade til fremstilling af aktivatoren og farmaceutisk praeparat indeholdende denne
GR3006760T3 (https=)
SU871525A1 (ru) Способ получени НАД-зависимой формиатдегидрогеназы
SU1479513A1 (ru) Способ получени формиатдегидрогеназы

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970505